Annovis Bio Return on Equity

Annovis Bio (ANVS) currently reports a ROE of 933.1%. That is above the Healthcare sector average of 20.77%. Use the charts on this page to explore Annovis Bio's ROE history and peer comparisons.

Annovis Bio's ROE of 933.1% is higher than the Healthcare sector average of 20.77%. That is roughly 4393.3% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Annovis Bio's current 933.1% should be judged against Healthcare norms (sector average: 20.77%) and against ANVS's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 933.1%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 20.77%. From there, open related valuation or income-statement pages for Annovis Bio, and consider following ANVS for alerts when major investors trade the stock.

Annovis Bio is classified in the Healthcare sector. On ROE, it currently shows 933.1% versus a sector average near 20.77%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ANVS with unrelated industries.